Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA271407
- Recipient
-
Fred Hutchinson Cancer Center UEI TJFZLPP6NYL6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,551,903
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 89% complete
- Place of performance
- Seattle, WA 98109, USA
Award details come from USAspending.gov.
Description
- Abstract
- Melanoma is the deadliest form of skin cancer. Its incidence is on the rise with 106,000 new cases expected in the U.S. In 2021. Immune checkpoint inhibitors (ICIS) have revolutionized the treatment of early and advanced melanoma, with concurrent anti-ctla-4 and anti-PD-1 monoclonal antibodies demonstrating a response in ~50% of patients, including highly durable responses. Unfortunately, there are no adequate biomarkers to predict response to single agent or combination ICI, and dual checkpoint blockade is associated with significant grade 3/4 immune-related adverse events (IRAES) in ~55% of patients. The goals of our ptrc are designed to address two unmet clinical needs: (I) improve our understanding of mechanisms of resistance to ICIS to design more effective immunotherapies and combinations, and (II) identify potential biomarkers to select patients appropriately for single agent VS combination immunotherapies and to predict and monitor IRAES. In our preclinical arm, we will perform integrated proteogenomic analysis of clinically annotated, pre-treatment biopsies from melanoma patients who received ICI. The data will be analyzed in the context of clinical annotations to refine an existing signature of melanoma ICI response identified by our team and to further elucidate mechanisms of ICI response/resistance and signatures associated with IRAES. In our clinical arm, we will analyze clinical trial biospecimens using MRM-based assays to confirm & extend findings generated in the preclinical arm.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $829,054 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $119,054 | |
| Amendment | $1,071,493 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,122,409 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,156,887 | |
| Amendment | $0 | |
| Original award | $1,253,006 |
Show all 13
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Mount Sinai Hospital | $103,790 | |
| New York University | $38,195 | |
| Weill Medical College Of Cornell University | $10,319 | |
| University Of Washington | $17,711 | |
| Weill Medical College Of Cornell University | $37,668 | |
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $83,380 | |
| Icahn School Of Medicine At Mount Sinai | $92,730 | |
| University Of Washington | $17,239 | |
| New York University | $8,490 | |
| New York University | $8,490 | |
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $75,147 | |
| University Of Washington | $14,026 | |
| Icahn School Of Medicine At Mount Sinai | $69,998 | |
| New York University | $42,968 |
Show all 14
Quick answers
Who received award U01CA271407?
U01CA271407 was awarded to Fred Hutchinson Cancer Center by National Cancer Institute (National Institutes of Health) on June 16, 2022.
How much is award U01CA271407 worth?
$5,551,903 has been obligated on U01CA271407.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award